​​​YOUR CONSTANT IN TISSUE-BASED BIOMARKER DISCOVERY

Copyright © Critical X Solutions, LLC
All Rights Reserved 

​Critical X

Critical X

Critical X Solutions and Vitro Molecular Laboratories Announce Companion and Complementary Diagnostic Co-Development and Commercialization Agreement 
Houston, TX – December 11th, 2017

About Critical X Solutions, LLC: Critical X is a research and development service laboratory providing rapid and reliable tissue-based study design and execution to the biomedical research community. Our service offerings incorporate advanced histologic methods as well our proprietary Cx Array technology - a flexible, high-throughput test system for multiplexed assays on formalin- fixed paraffin-embedded tissue sections. This technology has the potential to replace the traditional microscope slide as the testing vessel of choice for many of today’s tissue-based assays.


About Vitro Molecular Laboratories, LLC: Vitro is an “out of the box” international anatomic pathology specialty laboratory with a focus on providing esoteric services, including, but not limited to, immunohistochemistry, fluorescence in situ hybridization (FISH), cytogenetics, flow cytometry, and molecular testing.


For more information visit www.cxbio.tech or www.vitromolecular.com

Houston, TX – December 11th, 2017 – Critical X and Vitro Molecular announce companion and complementary diagnostic co-development and commercialization agreement.

The agreement covers the development and commercialization of companion and complementary diagnostics for cancer tissue diagnostics, focusing primarily on multiplexed assays that address challenging diagnostic scenarios.

Under the terms of the agreement, Vitro will explore and identify diagnostically challenging scenarios and commission projects to Critical X, where upon Critcal X will assess technical feasibility and develop the assay operationalization approach and assay conditions. The resulting intellectual property will be jointly held for licensing and each company will retain rights to the commercialization of the resulting assays as a part of their service portfolio.

"We are excited to work with Hadi Yaziji, MD and the Vitro Molecular team. The combination of Critical X’s unique tissue-based assay development background and proprietary technologies combined with Vitro’s unique niche and experience in companion diagnostic / clinical trial testing and commitment to quality make this partnership an ideal match that will deliver great value to clinical and research customers served by both companies.”, said Carlos Genty, Founder and Managing Director at Critical X.

“We echo the excitement of our colleagues at Critical X and look forward to a productive relationship that will surely benefit many biotechnology and oncology organizations. Critical X expertise in finding unique solutions to unique problems in the tissue-based testing space is unparalleled, and we are fortunate to team up with them in this endeavor”, said Hadi Yaziji, MD, Medical Director of Vitro Molecular Laboratories.